Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (“CBD”) and synthetic CBD medicines intended to address the unmet needs of large patient populations, today announced it has appointed Dr. Jeff Paley, M.D., to its Board of Directors.
Dr. Paley currently is, and has been, a practicing clinician and a consultant to the healthcare industry for the past 22 years. During this time, he has consulted for several biotech and pharmaceutical companies as well as over 30 equity analysts and investment portfolio managers reporting on and investing in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology industries. In this capacity, he analyzes and evaluates the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices.
“Dr. Paley is an insightful analyst of life sciences pre-clinical and clinical data with a comprehensive understanding of the US pharmaceutical regulatory landscape,” said Kalytera’s CEO Seth Yakatan. “As a Board member, he brings an analyst’s dispassionate perspective on the clinical trial process to help guide the Company to its most efficient and productive path in this mission critical function. I am delighted to have his specialized expertise on our Board, and pleased to welcome him to Kalytera.”
Commenting on his appointment to the Kalytera Board, Dr. Paley said, “As a practicing clinician, I routinely see patients suffering from debilitating diseases that are all too common. I believe Kalytera, and its world class research partners, are engaged in potentially ground breaking research with important prospects for developing new pharmaceutical therapies. I am excited to start, and look forward to making a positive contribution to realizing Kalytera’s fullest potential and improving the state of patient care globally.”
Dr. Jeff Paley Bio
Dr. Jeff Paley, M.D., currently is, and has been, an active clinician and a consultant to the healthcare industry for the past 22 years. During this time, he has consulted for several biotech and pharmaceutical companies as well as over 30 equity analysts and investment portfolio managers reporting on and investing in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology industries. In this capacity, he analyzes and evaluates the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices.
He founded Access Medical Associates in 2003. Previously, he spent five years on the full-time academic faculty of Weill Cornell Medical College where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. There, he acted as a principal or co-principal investigator on several studies of diabetes, hypertension, and cholesterol disorders including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. His additional clinical interests include sleep disorders, weight loss, adult attention-deficit disorder, and cardiovascular disease prevention. He has served as a member of the Board of Directors of Retrophin, Kellbenx, Inc. and Remote Radiology, Inc.
Dr. Paley trained at Harvard Medical School and completed a residency in internal medicine at Massachusetts General Hospital. He earned a Bachelor’s Degree in mathematics and Rabbinic Ordination from Yeshiva University.
Kalytera Therapeutics, Inc. is a pharmaceutical company that is developing a portfolio of nonpsychoactive cannabinoid and cannabinoid-modulating medicines that address the unmet needs of large patient populations. The Company seeks to commercialize its proprietary, synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone healing and osteoporosis. For more information, visit: https://kalytera.co/.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.